Drug Price Trends for ORPHENADRINE ER

Average Pharmacy Cost for ORPHENADRINE ER

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
ORPHENADRINE ER 100 MG TABLET	00185-0022-01	0.45815	EACH	2025-06-18
ORPHENADRINE ER 100 MG TABLET	43386-0480-24	0.45815	EACH	2025-06-18
ORPHENADRINE ER 100 MG TABLET	43386-0480-26	0.45815	EACH	2025-06-18
ORPHENADRINE ER 100 MG TABLET	00185-0022-01	0.46184	EACH	2025-05-21

Orphenadrine ER Market Analysis and Price Projections

Last updated: December 31, 2024

Introduction to Orphenadrine ER

Orphenadrine ER, a skeletal muscle relaxant, is widely used to alleviate pain and discomfort associated with muscle spasms and tension. The drug is available in various forms, including extended-release tablets and injectable solutions, making it a versatile option for pain management.

Market Growth and Drivers

The global Orphenadrine Citrate market, which includes Orphenadrine ER, is poised for significant growth. Here are the key drivers:

Increasing Prevalence of Musculoskeletal Disorders

The rising incidence of chronic pain conditions and musculoskeletal disorders is a major driver. As the population ages, the demand for effective pain management solutions is escalating, contributing to the market's growth[1].

Trend Towards Non-Opioid Pain Management

Healthcare providers are increasingly seeking non-opioid alternatives to minimize the risks associated with opioid use. This trend is expected to bolster the demand for Orphenadrine ER, as it offers a safer option for patients[1].

Advancements in Pharmaceutical Formulations

Ongoing research and development efforts are leading to improved formulations and potential new indications for Orphenadrine Citrate. These advancements enhance the drug's efficacy and patient compliance, further driving market growth[1].

Rising Healthcare Expenditure and Access

Increasing healthcare expenditure and greater access to healthcare services in emerging markets are anticipated to contribute significantly to the market's expansion. This ensures wider availability and adoption of Orphenadrine ER in pain management protocols[1].

Market Size and Forecast

The global Orphenadrine Citrate market is anticipated to grow at a compound annual growth rate (CAGR) of 11.46% between 2024 and 2031. The market is expected to transition from a valuation of USD 24.57 billion in 2024 to USD 52.51 billion by 2031[1].

Regional Market Analysis

Asia-Pacific

This region is a rapidly growing market for Orphenadrine Citrate, driven by countries such as China, Japan, India, and South Korea. The large population, rising disposable income, and increasing urbanization in these countries are leading to greater demand for Orphenadrine ER products and services[1].

Europe

Europe is another major region, characterized by a mature market with well-established infrastructure and consumer preferences. Countries like the United Kingdom, Germany, France, and Italy are key players in this region[1].

Latin America

Latin America presents both opportunities and challenges, with countries like Brazil, Mexico, and Argentina being key players. Economic fluctuations and political instability in some countries can impact market dynamics and consumer behavior[1].

Middle East and Africa

The Middle East and Africa represent emerging markets, with countries like UAE, Saudi Arabia, South Africa, and Nigeria showing promising growth potential. Economic diversification efforts, urbanization, and a young population are driving demand for Orphenadrine ER products and services in the region[1].

Pricing and Cost Analysis

Extended-Release Tablets

The cost for Orphenadrine ER 100 mg oral tablets can range from approximately $21.52 for 20 tablets to $310.11 for 500 tablets, depending on the quantity and pharmacy[2].

Injectable Solutions

The price for Orphenadrine injectable solution can range from $131.90 for 20 milliliters to $407.30 for 50 milliliters, highlighting the variability in pricing based on the quantity and formulation[2].

Import and Export Prices

Import data shows that the prices for Orphenadrine Citrate can vary significantly based on the origin, destination, and quantity. For example, a shipment of 469 kg of Orphenadrine Citrate tablets was valued at $27,236.83, while a shipment of 2700 tablets was valued at $3,222.08[3].

Competitive Landscape

The Orphenadrine Citrate market is characterized by several key players, including Struchem, Ningbo Inno Pharmchem, Aceto, TNJ Chemical, and Finetech Industry Limited. These companies are involved in strategic consolidations, mergers, and acquisitions to expand their product portfolios and leverage synergies to drive growth and competitiveness[1].

Mergers and Acquisitions

The market is witnessing a wave of mergers and acquisitions as companies seek to consolidate their market positions. These strategic moves provide access to new technologies, intellectual property, and talent, enabling companies to innovate faster and stay ahead of market trends[1].

Patient Assistance and Copay Programs

While there are no specific patient assistance programs (PAPs) found for Orphenadrine ER, patients can benefit from discount cards and copay programs that can significantly reduce the cost of the medication. For instance, the Drugs.com Discount Card can save patients up to 80% on prescription medicines[2].

Safety and Efficacy

Orphenadrine ER has a well-established safety profile, with over 45 years of global post-marketing surveillance. The drug's efficacy for relieving pain due to muscle spasm is supported by clinical trial evidence, although adverse effects such as dry mouth, palpitations, and dizziness can occur, particularly at higher doses[4].

Key Takeaways

• Market Growth: The Orphenadrine Citrate market is expected to grow at a CAGR of 11.46% from 2024 to 2031.
• Drivers: Increasing musculoskeletal disorders, trend towards non-opioid pain management, advancements in formulations, and rising healthcare expenditure.
• Regional Markets: Asia-Pacific, Europe, Latin America, and Middle East & Africa are key regions with varying growth potentials.
• Pricing: Prices vary based on formulation, quantity, and pharmacy, with extended-release tablets and injectable solutions having different cost structures.
• Competitive Landscape: Key players are engaging in mergers and acquisitions to enhance market positions.
• Safety and Efficacy: Orphenadrine ER has a well-established safety profile with clinical evidence supporting its efficacy.

FAQs

What is the expected growth rate of the Orphenadrine Citrate market from 2024 to 2031?

The Orphenadrine Citrate market is anticipated to grow at a compound annual growth rate (CAGR) of 11.46% from 2024 to 2031[1].

What are the primary drivers of the Orphenadrine Citrate market growth?

The primary drivers include the increasing incidence of musculoskeletal disorders, the trend towards non-opioid pain management, advancements in pharmaceutical formulations, and rising healthcare expenditure[1].

Who are the key players in the Orphenadrine Citrate market?

Key players include Struchem, Ningbo Inno Pharmchem, Aceto, TNJ Chemical, and Finetech Industry Limited[1].

What are the common side effects of Orphenadrine ER?

Common side effects include dry mouth, palpitations, confusion, and dizziness, particularly in elderly patients and at higher doses[4].

Are there any patient assistance programs available for Orphenadrine ER?

As of the latest data, there are no specific patient assistance programs (PAPs) for Orphenadrine ER, but patients can benefit from discount cards and copay programs[2].

How does the pricing of Orphenadrine ER vary?

Pricing varies based on the formulation (extended-release tablets or injectable solutions), quantity, and pharmacy, with significant price differences observed in import and export data[2][3].

Sources

1. Orphenadrine Citrate Market Size, Share and Forecast By Key Players - OpenPR
2. Orphenadrine Prices, Coupons, Copay Cards & Patient Assistance - Drugs.com
3. Citrate Usa,orphenadrine Citrate Imports in World - Volza.com
4. Orphenadrine - Therapeutic Goods Administration (TGA)